CD INFORM: Investigating Natalizumab Through Further Observational Research and Monitoring
Study Status
Open to Enrollment
Study Description
This research study is for men and women with moderate to severe Crohn’s disease who are currently being treated with TYSABRI.
The purpose of the study is to collect information on serious infections, cancers and other serious problems that occur in people with Crohn’s disease treated with TYSABRI. This is an observational study. No additional drugs will be administered during the study.
Participants will be followed for up to 5 years.
Disease Status and/or Stage
Crohn's Disease Being Treated with TYSABRI
Sponsor
Elan Pharmaceuticals
Key Eligibility
- Men and women with Crohn's disease
- Being treated with TYSABRI
Principal Investigator
Contact
- Jill Roberts Center for Inflammatory Bowel Disease
- (212) 746-5077
Healthy Volunteers
As a healthy volunteer in a clinical trial you may make a significant contribution to the discovery of medical knowledge and new treatments that could impact people around the world.
Click here for studies seeking healthy volunteers.
Contact Us
For general inquiries, or if you need assistance finding a study, please contact:
Robert Hagerty
Subject Recruitment Manager
Tel: (646) 962-9340
[email protected]
